Search Videos and More
CAR-T Cell Therapy for Lymphoma: Updates and Progress
Caron Jacobson, MD, MMSc, gives updates and shares progress with CAR-T cell therapy for lymphoma.Hematologic Malignancies CME: 2021
The care of patients with hematologic malignancies is evolving rapidly. These video highlights discuss new developments in the diagnosis and treatment of hematologic malignancies presented at the 2021 Annual Meeting of the American Society of Hematology (ASH).Blood Cancer Research: Clinical Trial Helps Younger Patient
A patient shares her journey getting diagnosed with chronic lymphocytic leukemia in her 30's. Dana-Farber Cancer Institute's Matthew Davids, MD, MMSc, enrolled her on a clinical trial and details the results of that study. The research is now getting presented at ASH21.ASH 2021 Highlights - CME
Register for 2021 ASH Highlights CMENew Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma
Dana-Farber Cancer Institute research shows elevated rates of a blood cancer precursor condition in groups at high risk for multiple myeloma.Blood Cancer Research: Clinical trial helps younger patient
Dr. Matthew Davids presented a study that demonstrated the ibrutinib+FCR drug combination keeps chronic lymphocytic leukemia in young patients in remission for several years.COVID-19 vaccine and blood cancer
Dr. Nikhil Munshi and colleagues reported a study demonstrating that COVID-19 vaccination offers less protection for multiple myeloma patients, reinforcing the need for these patients to use additional precautions.Blood Cancer: Higher rates of precursor in high-risk individuals
Dr. Irene Ghobrial and Dr. Habib El-Khoury shared the first results from the Promise study, which screens individuals at high risk for multiple myeloma.Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years
A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions for patients with chronic lymphocytic leukemia (CLL).Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma
Molecular and genetic research by scientists at Dana-Farber Cancer Institute has advanced the categorization of different risk groups in patients with smoldering myeloma, a premalignant condition that can – but doesn’t always – progress to the blood cancer, multiple myeloma.American Society of Hematology (ASH) Annual Meeting
As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute shared advances and insights at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 11–14, 2021 in Atlanta, GeorgiaNew Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma
The first results from the largest screening study yet conducted in the United States of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.